Spots Global Cancer Trial Database for second or third line therapy
Every month we try and update this database with for second or third line therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy | NCT03626545 | Non-Small-Cell ... | Canakinumab Docetaxel Placebo | 18 Years - | Novartis | |
Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line Therapy | NCT03626545 | Non-Small-Cell ... | Canakinumab Docetaxel Placebo | 18 Years - | Novartis |